Neoadjuvant immunotherapy for advanced, resectable non–small cell lung cancer: A systematic review and meta‐analysis
Yajing Wu(Hebei Medical University), Joe Y. Chang(The University of Texas MD Anderson Cancer Center), Fei Liang(Sun Yat-sen University), Carl M. Gay(The University of Texas MD Anderson Cancer Center), Vivek Verma(The University of Texas MD Anderson Cancer Center), Jianing Wang(Hebei Medical University), Jun Wang(Hebei Medical University), Min Zhao(Hebei Medical University), Qiang Lin(Hebei Medical University), Yujia Chen(Guizhou University), Wei Zhang(Temple University), Zhouguang Hui(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 36
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2019|1k
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|746